Peripartum cardiomyopathy is idiopathic heart failure occurring in the absence of any determinable heart disease during the last month of pregnancy or the first 5 months postpartum.Load more
Peripartum cardiomyopathy is idiopathic heart failure occurring in the absence of any determinable heart disease during the last month of pregnancy or the first 5 months postpartum.
Diagnostic echocardiographic criteria include left ventricular ejection fraction <0.45, M-mode fractional shortening <30% and end-diastolic dimension >2.7 cm/m2. ECG, MRI, endomyocardial biopsy, and cardiac catheterisation aid in the diagnosis and management of peripartum cardiomyopathy.
Treatment includes conventional pharmacologic heart failure therapies, principally diuretics, angiotensin-converting enzyme inhibitors, vasodilators, digoxin, beta-blockers and anticoagulants. Targeted therapies (such as intravenous immunoglobulin, pentoxifylline, and bromocriptine) have shown promise in small trials, but require further evaluation. Despite a mortality rate of up to 10% and a high risk of relapse in subsequent pregnancies, many patients with peripartum cardiomyopathy recover within 3 to 6 months of disease onset.Load Less
Sara C Martinez, Sharonne N HayesUS Cardiology Review, 2016;10(1):14–20DOI: http://dx.doi.org/10.15420/usc.2016.10.1.14
John Anthony, Karen SliwaCardiac Failure Review 2016;2(1):20–6DOI: https://doi.org/10.15420/cfr.2015:24:2